Get started
Work

13 Efficacy on individualized starting dose (ISD) and fixed starting dose (FSD) of niraparib per investigator-assessment (IA) in newly diagnosed advanced ovarian cancer (OC)

Year: 2020
Type: article
DOI: 10.1136/ijgc-2020-igcs.13
Authors: W. Graybill, M. Mirza, A. González-Martin, D. O’Malley, L. Gaba, O.W.S. Yap, E. Guerra, P.G. Rose, J. Baurain, S. Ghamande, H. Denys, E. Prendergast, C. Pisano, P. Follana, E.I. Braicu, P.M. Calvert, J. Korach, Y. Li, D. Gupta, B.J. Monk
Institutions: Gynecologic Oncology Group, Medical University of South Carolina, Copenhagen University Hospital, Rigshospitalet, Nordic Society of Gynecologic Oncology, Clinica Universidad de Navarra, Spanish Ovarian Cancer Research Group, The Ohio State University, Hospital Clínic de Barcelona, Hospital Universitario Ramón y Cajal, Cleveland Clinic, Cliniques Universitaires Saint-Luc, UCLouvain, Augusta University, Ghent University Hospital, Minnesota Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Centre Antoine Lacassagne, Charité - Universitätsmedizin Berlin, Cancer Trials Ireland, Sheba Medical Center, GlaxoSmithKline (United States), University of Arizona, The US Oncology Network, Arizona Oncology
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W3098466880
FWCI: 0.241
Cites:
Cited by: 5
Related to: 10